Product Description
Mechanisms of Action: Utrophin Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Summit
Company Location: CAMBRIDGE MA 02142
Company CEO: Robert W. Duggan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Muscular Dystrophy, Duchenne
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PoC Study to Assess Activity and Safety of SMT C1100 in Boys with DMD | P2 |
Completed |
Muscular Dystrophy, Duchenne |
2018-09-11 |
|
| SMT C11005 | P2 |
Terminated |
Muscular Dystrophy, Duchenne |
2018-04-11 |
|
| SMTC11004 - Phase 1 study in healthy volunteers and DMD patients | P1 |
Completed |
Muscular Dystrophy, Duchenne |
2016-06-28 |
|
| Modified Diet Trial | P1 |
Completed |
Muscular Dystrophy, Duchenne |
2015-08-01 |